Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets

Lancet Glob Health. 2016 Feb;4(2):e94-5. doi: 10.1016/S2214-109X(15)00269-7.

Authors

Lekha Puri¹, Collins Oghor¹, Claudia M Denkinger², Madhukar Pai³

Affiliations

¹ McGill International Tuberculosis Center, McGill University, Montreal, Canada.
² FIND, Geneva, Switzerland.
³ McGill International Tuberculosis Center, McGill University, Montreal, Canada; Department of Epidemiology and Biostatistics, 1020 Pine Avenue West, Montreal QC H3A 1A2, Canada. Electronic address: madhukar.pai@mcgill.ca.

PMID: 26823226
DOI: 10.1016/S2214-109X(15)00269-7

No abstract available

Publication types

Letter

MeSH terms

Commerce*
DNA, Bacterial / analysis
Health Care Costs*
Health Care Sector / economics
Health Services Accessibility / economics*
Humans
Molecular Diagnostic Techniques / economics*
Mycobacterium tuberculosis* / genetics
Private Sector
Rifampin*
Tuberculosis, Multidrug-Resistant / diagnosis*

Substances

DNA, Bacterial
Rifampin